. Author manuscript; available in PMC: 2023 Apr 1.

Published in final edited form as: Eur J Heart Fail. 2022 Mar 14;24(4):685–693. doi: 10.1002/ejhf.2463

Table 3.

Factors associated with the composite of death, cardiac transplantation or left ventricular assist device implantation after cardiac resynchronization therapy in patients with LMNA cardiomyopathy

Variable	Univariable		Multivariable^a
	HR (95% CI)	p-value	HR (95% CI)	p-value
MRA pre-CRT	2.676 (1.489–4.809)	0.001
NYHA class pre-CRT	1.930 (1.203–3.098)	0.007	1.821 (1.069–3.101)	0.027
NT-proBNP pre-CRT	1.000 (1.000–1.001)	0.001
Loop diuretic pre-CRT	1.01 (1.005–1.013)	<0.0001	1.005 (1.000–1.009)	0.037
Ventricular pacing % pre-CRT	0.991 (0.981–1.001)	0.073
LVEF pre-CRT	0.946 (0.921–0.972)	<0.001	0.933 (0.900–0.968)	0.0002
CRT responder at 6 months	0.580 (0.338–0.995)	0.048	0.296 (0.149–0.585)	0.001

CI, confidence interval; CRT, cardiac resynchronization therapy; HR, hazard ratio; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association.

n = 75 for the multivariable model.